How Has the Ovarian Cancer Diagnostics Market Size Evolved in Recent Years?
The ovarian cancer diagnostics market has seen considerable growth due to a variety of factors.
•The market size for ovarian cancer diagnostics has seen robust growth in recent times. It is projected to expand from $2.74 billion in 2024 to $2.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.6%.
The significant growth during the historic period can be traced back to advances in biomarker discovery and validation, increased usage of transvaginal ultrasound, heightened awareness of BRCA gene mutations, research into tumor markers, and the introduction of various screening programs and guidelines.
What are the Market Size and Expected Growth Rates for the Ovarian Cancer Diagnostics Market?
The ovarian cancer diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the ovarian cancer diagnostics market size is anticipated to experience robust growth. The market is projected to escalate to a value of $3.93 billion in 2029, reflecting a compound annual growth rate (CAGR) of 7.6%.
This growth over the forecast period can be ascribed to a variety of factors such as early detection efforts, a rise in ovarian cancer cases, the incorporation of artificial intelligence (AI), tailored medicine strategies, the introduction of innovative biomarkers, and advancements in genomic and proteomic profiling. The forecast period will also witness several significant trends including the application of biosensor technologies for early diagnosis, the incorporation of digital pathology, developments in imaging methodologies, enhancements in imaging technologies, and progress in pathology techniques.
Which Key Drivers Are Propelling The Ovarian Cancer Diagnostics Market's Growth?
The surge in ovarian cancer prevalence is anticipated to drive growth within the market for ovarian cancer diagnosis. Ovarian cancer, a malicious tumor that originates in the ovaries - the egg-producing and hormone-responsible organs in women - has seen its prevalence rise due to extended life spans, late pregnancies, and lifestyle alterations. Diagnostics for ovarian cancer can alleviate its prevalence by facilitating early detection and immediate intervention, which in turn, means swift treatment and better prognoses. For example, in 2022, the World Ovarian Cancer, a Canada-based body striving to raise ovarian cancer awareness globally, projected that by 2050 the worldwide incidence of ovarian cancer amongst women will have spiked by over 55%, hitting around 503,448 cases. Furthermore, the yearly death toll from ovarian cancer is estimated to soar to 350,956, reflecting a nearly 70% increase as opposed to 2022. Hence, the escalating prevalence of ovarian cancer is fuelling the expansion of the ovarian cancer diagnosis market.
What Are The Key Segments Within The Global Ovarian Cancer Diagnostics Market?
The ovarian cancer diagnostics market covered in this report is segmented –
1) By Product Type: Instruments, Kits, Reagents
2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types
3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Other Cancer Types
4) By End User: Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes
Subsegments:
1) By Instruments: Imaging Systems, Biopsy Devices, Molecular Diagnostic Instruments
2) By Kits: Diagnostic Test Kits, Screening Kits
3) By Reagents: Antibodies, Enzymes, Assay Reagents
Pre-Book The Ovarian Cancer Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Ovarian Cancer Diagnostics Market?
The prominence of advanced diagnostic technology is a significant emerging trend in the ovarian cancer diagnostics market. Firms in the ovarian cancer diagnostics sector are integrating advanced diagnostic technologies into their operations to maintain their market presence. For example, in November 2022, Hoffmann-La Roche AG - a Switzerland-based pharmaceutical and healthcare firm - got FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This is the first immunohistochemistry (IHC) based complementary diagnostic test kit purposed for identifying ovarian cancer patients who are suitable for the ovarian cancer prescription medication, ELAHERE. This test has been uniquely crafted to gain crucial insights and procure comprehensive clinical information about the state of ovarian cancer, thereby contributing to enhanced disease control and patient results.
Who Are the Key Players in the Ovarian Cancer Diagnostics Market?
Major companies operating in the ovarian cancer diagnostics market include:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Eli Lilly and Company
• GE HealthCare Technologies Inc.
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Hologic Inc.
• Illumina Inc.
• PerkinElmer Inc.
• Sysmex Corporation
• Bio-rad Laboratories Inc.
• Qiagen N.V.
• Natera Inc.
• Myriad Genetics Inc.
• ArcherDX Inc.
• Invitae Corporation
• Guardant Health
• Luminex Corporation
• NanoString Technologies Inc.
• Siemens Healthcare Private Limited
• Menarini Silicon Biosystems S.p.A.
• Precipio Inc.
• Angle plc
What are the Regional Insights into the Ovarian Cancer Diagnostics Market?
North America was the largest region in the ovarian cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
